Get the Stockscreener App
2.67
1.11%
-0.03
Perspective Therapeutics Inc stock is traded at $2.67, with a volume of 1.86M.
It is down -1.11% in the last 24 hours and up +25.94% over the past month.
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
See More
Previous Close:
$2.70
Open:
$2.73
24h Volume:
1.86M
Relative Volume:
1.20
Market Cap:
$198.48M
Revenue:
$6.96M
Net Income/Loss:
$-46.51M
P/E Ratio:
-15.56
EPS:
-0.1716
Net Cash Flow:
$-37.99M
1W Performance:
+11.25%
1M Performance:
+25.94%
6M Performance:
-17.08%
1Y Performance:
-23.05%
1-Day Range:
$2.65
$2.89
1-Week Range:
$2.30
$2.89
52-Week Range:
$1.60
$5.3881
Perspective Therapeutics Inc Stock (CATX) Company Profile
Name
Perspective Therapeutics Inc
Sector
Industry
Phone
509-375-1202
Address
350 Hills Street, Suite 106, Richland
Compare CATX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CATX
Perspective Therapeutics Inc
|
2.67 | 200.71M | 6.96M | -46.51M | -37.99M | -0.1716 |
|
ABT
Abbott Laboratories
|
125.46 | 214.37B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
92.58 | 136.01B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
354.09 | 134.98B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
99.87 | 127.88B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
83.08 | 48.88B | 5.88B | 1.34B | 799.60M | 2.3489 |
Perspective Therapeutics Inc Stock (CATX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-24-25 | Resumed | Truist | Buy |
| Oct-10-25 | Initiated | BTIG Research | Buy |
| Mar-13-25 | Initiated | H.C. Wainwright | Buy |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-25-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-01-24 | Initiated | Wedbush | Outperform |
| Sep-25-24 | Initiated | Truist | Buy |
| Jul-25-24 | Initiated | BofA Securities | Buy |
| May-09-24 | Initiated | Cantor Fitzgerald | Overweight |
View All
Perspective Therapeutics Inc Stock (CATX) Latest News
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Receives Average Rating of “Buy” from Brokerages - Defense World
Perspective Therapeutics Inc (CATX) Performance and Fundamentals Dashboard tells a completely different story - Setenews
What Is the Future of Remi Edelstahl Tubulars Limited Stock Expert Projections ExplainedCapital Gains Strategies & Maximize Gains Professionally - earlytimes.in
DHP India Limited Included in Top Momentum ScanRetail Trading Trends & Consistent Double Returns - earlytimes.in
What analysts say about Perspective Therapeutics Inc AAJ0 stockMorning Star Patterns & Download Your Free Wealth Map PDF - earlytimes.in
Affinity Asset Advisors LLC Decreases Holdings in Perspective Therapeutics, Inc. $CATX - Defense World
Perspective Therapeutics (NASDAQ: CATX) sees FMR disclose 0.4% stake - Stock Titan
Can Perspective Therapeutics Inc. stock sustain breakout momentumQuarterly Portfolio Report & High Accuracy Trade Signal Alerts - Newser
CATX SEC FilingsPerspective Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ASCO Gastrointestinal Cancers Symposium - marketscreener.com
Perspective Therapeutics Announces Acceptance of VMT-α-NET - GlobeNewswire
How Perspective Therapeutics Inc. stock moves on employment dataEarnings Recap Summary & Growth-Oriented Investment Plans - Newser
Can Perspective Therapeutics Inc. stock ride next bull market cycle2025 Analyst Calls & AI Enhanced Trade Execution Alerts - Newser
Is Perspective Therapeutics Inc. stock attractive for growth fundsWeekly Trend Summary & Weekly Watchlist for Consistent Profits - Newser
How Perspective Therapeutics Inc. stock reacts to oil pricesGlobal Markets & Expert Curated Trade Setup Alerts - Newser
How Perspective Therapeutics Inc. stock compares with market leadersQuarterly Trade Summary & Long-Term Safe Return Strategies - Newser
Why Perspective Therapeutics Inc. (AAJ0) stock is listed among top recommendationsWeekly Trend Report & Technical Entry and Exit Tips - Newser
What downside risks could hit Perspective Therapeutics Inc. (AAJ0) stockBull Run & Verified Stock Trade Ideas - Newser
How Perspective Therapeutics Inc. stock reacts to stronger dollarWeekly Risk Summary & Capital Efficient Trading Techniques - Newser
Does Perspective Therapeutics Inc. (AAJ0) stock trade below intrinsic value2025 Valuation Update & Risk Controlled Stock Pick Alerts - Newser
Perspective Therapeutics Updates Corporate Presentation on Advancements - TipRanks
[8-K] Perspective Therapeutics, Inc. Reports Material Event | CATX SEC FilingForm 8-K - Stock Titan
Perspective Therapeutics (CATX) 10K Form and SEC Filings 2025 - MarketBeat
Perspective Therapeutics (CATX) Receives a Buy from RBC Capital - The Globe and Mail
Check out these key findings about Perspective Therapeutics Inc (CATX) - setenews.com
Perspective Therapeutics (NASDAQ:CATX) Coverage Initiated by Analysts at Truist Financial - MarketBeat
EBIT per share of Perspective Therapeutics, Inc. – BER:AAJ0 - TradingView
CATX: Truist Securities Raises Price Target to $12.00 with Buy R - GuruFocus
Perspective Therapeutics (CATX) Stock Price, News & Analysis - MarketBeat
Perspective Therapeutics Inc Stock Analysis and ForecastMonthly Performance Summary & Bull Bear Market Updates - earlytimes.in
UBS Maintains Perspective Therapeutics (CATX) Buy Recommendation - Nasdaq
Perspective Therapeutics (CATX): UBS Maintains Rating but Lowers Price Target | CATX Stock News - GuruFocus
UBS lowers Perspective Therapeutics stock price target on competition concerns - Investing.com Nigeria
UBS lowers Perspective Therapeutics stock price target on competition concerns By Investing.com - Investing.com South Africa
Will Perspective Therapeutics Inc. stock outperform global peersQuarterly Market Summary & Consistent Growth Stock Picks - newser.com
Why Perspective Therapeutics Inc. stock could rally stronglyEarnings Summary Report & Risk Managed Investment Signals - newser.com
Is Perspective Therapeutics Inc. stock attractive for hedge fundsJuly 2025 Big Picture & AI Enhanced Trading Alerts - newser.com
Is Perspective Therapeutics Inc. stock attractive post correction2025 Volume Leaders & Expert Curated Trade Ideas - newser.com
B. Riley Expects Lower Earnings for Perspective Therapeutics - Defense World
What machine learning models say about Perspective Therapeutics Inc.Weekly Earnings Recap & Daily Oversold Bounce Ideas - newser.com
CATXPerspective Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
How geopolitical risks impact Perspective Therapeutics Inc. (AAJ0) stockJuly 2025 Summary & Daily Technical Stock Forecast Reports - newser.com
Perspective Therapeutics to Participate in Upcoming December Conferences - The Manila Times
Perspective Therapeutics, Inc. Announces Participation in Upcoming Healthcare Conferences for Investor Engagement - Quiver Quantitative
Can Perspective Therapeutics Inc. stock attract ESG investmentsWall Street Watch & Verified Momentum Stock Watchlist - newser.com
Will Perspective Therapeutics Inc. stock beat value stocks2025 Market Sentiment & Free AI Powered Buy and Sell Recommendations - newser.com
Will Perspective Therapeutics Inc. (AAJ0) stock keep high P E multiplesTrade Signal Summary & High Accuracy Trade Alerts - newser.com
Perspective Therapeutics Inc Stock (CATX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.28%
Cap:
|
Volume (24h):